The efficacy of pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte stimulating factor(rhG-CSF) in promoting hematopoiesis recovery after hematopoietic stem cell transplantation. Methods The data of 100 patients with malignant blood diseases who underwent hematopoietic stem cell transplantation in the Hematology Department of Shenzhen Second People's Hospital from January 2016 to December 2020 were retrospectively analyzed. They were randomly assigned to two groups with 1:1, which were accepted PEG-rhG-CSF and rhG-CSF after hematopoietic stem cell transfusion. 根据中文摘要重新翻译Results The time of neutrophil implantation in PEG-rhG-CSF group and rhG-CSF group was (18.7±3.4) days and (18.0±3.1) days respectively, P=0.281, showing no statistical difference. There were 26 cases of neutropenia with fever in PEG-rhG-CSF group and 29 cases in rhG-CSF group, with incidence of 53.06% and 56.86% (P=0.89), showing no statistical difference. The times of medication were 2.6 times (2-5 times) and 18.1 times (11-31 times), P<0.05, with significant statistical difference. The main adverse reactions were bone pain and muscle pain. Conclusion The outcomes of PEG-rhG-CSF group and rhG-CSF group were similar, PEG-rhG-CSF had the advantage of fewer times of medication.
Purpose: To investigate the association between myopia and ganglion cell layer and inner plexiform layer (GCIPL) in diabetic patients without clinically diabetic retinopathy (DR). Methods: Guangzhou Diabetic Eye study was a longitudinal study. A total of 1165 adults aged 30-80 years were recruited in this study which divided into 3 groups according to the presence of myopia (spherical equivalence, SE≤-3 diopters) and diabetics: healthy group (n=508); diabetes mellitus group (n=525); diabetes mellitus (DM)+myopia group(n=132). GCIPL was measured via swept-source optical coherence tomography. Univariable model and multivariable model were used to showing the association of GCIPL change and baseline parameters. Results: SE was 1.07±1.06D in healthy group, 1.02±1.00D in diabetes mellitus group and -5.36±2.30 D in DM + myopia group(P<0.001). The baseline GCIPL thickness were 71.1±0.3μm, 74.4±0.2 μm, 71.7±0.5μm, respectively. The slope of GCIPL thickness was -0.10 (95%CI: 0.05, -2.03) μm/year in healthy group, which was 12 folds faster than those in diabetes group (-1.21 [95%CI: 0.05, -24.04], P<0.001) μm/year and 22 folds higher among those in DM + myopia group (-2.17 [95%CI: 0.10, -21.63], P=0.009) μm/year. Conclusions: Both myopia and diabetes status accelerate macular ganglion cell layer and inner plexiform layer thinning in diabetic patients without diabetic retinopathy.
